Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 4/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 4/20 | 0.54 |
| ▸ | CA9 | Q16790 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496286 | 0.95 | ALDH1A1 (0.61) | ALDH1A1MAPTLMNATDP1MAPK1 | |
| SCHEMBL31605436 | 0.85 | ALDH1A1 (0.67) | ALDH1A1MAPTLMNATDP1MAPK1 | |
| SCHEMBL2103149 | 0.83 | ALDH1A1 (0.65) | ALDH1A1MAPTLMNATDP1MAPK1 | |
| SCHEMBL941084 | 0.83 | ALDH1A1 (0.65) | ALDH1A1MAPTLMNATDP1MAPK1 | |
| SCHEMBL10373626 | 0.81 | MAPT (0.77) | ALDH1A1MAPTLMNATDP1MAPK1 | |
| SCHEMBL4671150 | 0.81 | MEN1 (0.65) | ALDH1A1MAPTLMNAHTTHPGD | |
| SCHEMBL13591219 | 0.81 | MEN1 (0.69) | ALDH1A1MAPTLMNAMAPK1HSD11B1 | |
| SCHEMBL13591281 | 0.81 | AKR1C3 (0.47) | ALDH1A1MAPTLMNAHPGDPOLB | |
| SCHEMBL6242244 | 0.80 | CA2 (0.54) | HTTHSD11B1CA12CA1CA2 | |
| SCHEMBL2959258 | 0.80 | ALDH1A1 (0.57) | ALDH1A1MAPTLMNAMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1997370-A | Medicaments containing N-sulfamoyl-N' -arylpiperazines for the prophylaxis or treatment of obesity and related diseases | SOLVAY PHARM GMBH (DE) | 2007-07-11 | — | — | CN | claimed |
| EP-1750712-A2 | MEDICAMENTS CONTAINING N-SULFAMOYL-N'-ARYLPIPERAZINES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | Solvay Pharmaceuticals GmbH (DE) | 2007-02-14 | — | — | EP | claimed |
| WO-2005110413-A2 | MEDICAMENTS CONTAINING N-SULFAMOYL-N'-ARYLPIPERAZINES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-11-24 | — | — | WO | claimed |
| US-20050261292-A1 | Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-11-24 | — | — | US | claimed |
| WO-2025109563-A1 | SPIRO-HYDANTOIN DERIVATIVE EXHIBITING ADAMTS-4 INHIBITORY ACTIVITY, AND USE THEREOF | 서울대학교병원 | 2025-05-30 | — | — | WO | disclosed |
| WO-2019238057-A1 | APPLICATION OF FSO2N3 IN PREPARATION OF AZIDE | 中国科学院上海有机化学研究所 | 2019-12-19 | — | — | WO | disclosed |
| CN-1997370-B | Use of N-sulfamoyl-N' -arylpiperazines for the production of medicaments for the prophylaxis or treatment of obesity and related diseases | SOLVAY PHARM BV | 2011-06-01 | — | — | CN | disclosed |
| EP-1951725-B1 | N-SULFAMOYL-N -BENZOPYRANPIPERIDINES AS INHBITORS OF CARBONIC ANHYDRASES | ABBOTT PRODUCTS GMBH (DE) | 2010-11-03 | — | — | EP | disclosed |
| US-7772225-B2 | N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-7547708-B2 | N-sulfamoyl-N′-benzopyranpiperidine compounds and uses thereof | SOLVAY PHARMACEUTICALS, INC. (DE) | 2009-06-16 | — | — | US | disclosed |
| CN-101326166-A | Novel N-sulfamoyl-piperidine amides for the prevention or treatment of obesity and related disorders | SOLVAY PHARM GMBH (DE) | 2008-12-17 | — | — | CN | disclosed |
| CN-101309923-A | N-sulfamoyl-N' -benzopyran piperidines as carbonic anhydrase inhibitors | SOLVAY PHARM GMBH (DE) | 2008-11-19 | — | — | CN | disclosed |
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH | 2007-06-28 | — | — | US | disclosed |
| WO-2007065948-A1 | NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
| US-20070117823-A1 | N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof | SOLVAY PHARMACEUTICALSS GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
| WO-2007054580-A1 | N-SULFAMOYL-N’-BENZOPYRANPIPERIDINES AS INHBITORS OF CARBONIC ANHYDRASES | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-05-18 | — | — | WO | disclosed |
| EP-1750712-A2 | MEDICAMENTS CONTAINING N-SULFAMOYL-N'-ARYLPIPERAZINES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | Solvay Pharmaceuticals GmbH (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005110413-A2 | MEDICAMENTS CONTAINING N-SULFAMOYL-N'-ARYLPIPERAZINES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050261292-A1 | Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| CN-1322204-A | Oxazolidinone antibacterial agents having thiocarbonyl functionality | PHARMACIA & VPJOHN CO (US) | 2001-11-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | FABP4, GPR119, SRM | ALDH1A1 200/4885MAPT 4242/4885LMNA 3379/4885 |
| US-20070117823-A1 | N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof | SCN2A, NAPEPLD, SCN5A | ALDH1A1 605/4885MAPT 430/4885LMNA 2345/4885 |
| US-20050261292-A1 | Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions | GPR119, FABP4, SULT2A1 | ALDH1A1 265/4885MAPT 3810/4885LMNA 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.